Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04385849 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19
A Phase 1 study, sponsored by ImmunityBio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04385849 is a Phase 1 study that was terminated before completion, run by ImmunityBio. The registered enrollment target is 1 participants.
The verdict
NCT04385849, a Phase 1 study, was terminated before completion, sponsored by ImmunityBio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a phase 1b, randomized, blinded, placebo-controlled study in adult subjects with COVID-19. This clinical trial is designed to assess the safety and immunostimulatory activity of N-803.
Interventions
- OTHER Saline
- BIOLOGICAL N-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2020-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04385849
The ClinicalTrials.gov registry entry for NCT04385849 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04385849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04385849 about?
NCT04385849 is a clinical study titled "Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19". This is a phase 1b, randomized, blinded, placebo-controlled study in adult subjects with COVID-19. This clinical trial is designed to assess the safety and immunostimulatory activity of N-803.
What is the current status of trial NCT04385849?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-07-22. Estimated completion is 2020-07-25.
What interventions are being tested in trial NCT04385849?
The interventions under investigation include: Saline (OTHER), N-803 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04385849?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.